Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) shares dropped 0.9% during trading on Thursday . The company traded as low as C$26.86 and last traded at C$27.18. Approximately 1,527,091 shares changed hands during mid-day trading, a decline of 3% from the average daily volume of 1,579,271 shares. The stock had previously closed at C$27.44.

VRX has been the subject of a number of research analyst reports. Royal Bank of Canada lowered their target price on Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating for the company in a research note on Friday, October 20th. TD Securities upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 target price for the company in a research note on Wednesday, November 8th.

The firm has a market capitalization of $9,120.00, a PE ratio of 5.34 and a beta of -0.67.

In related news, Director Schutter Richard Urbain De acquired 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Friday, November 17th. The stock was bought at an average price of C$14.33 per share, with a total value of C$143,300.00.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International (VRX) Stock Price Down 0.9%” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with's FREE daily email newsletter.